Skip to main
MGTX
MGTX logo

MGTX Stock Forecast & Price Target

MGTX Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MeiraGTx Holdings PLC is positioning itself for sustained growth with an extended financial runway into 2027, bolstered by the anticipated closing of the Hologen deal. The company is demonstrating significant advancements in its clinical pipeline, particularly in ophthalmology, with all patients in recent trials showing improvements in visual acuity and overall patient outcomes. Additionally, the upcoming Biologics License Application (BLA) filing in 2026, supported by promising Phase II results, underscores the company’s commitment to developing effective and safe gene therapies, enhancing its long-term financial prospects.

Bears say

MeiraGTx Holdings PLC is facing a significant risk related to the potential inability to secure regulatory approval for its pipeline products, which could lead to downward revisions in projections and negatively affect financial performance. The company's reported net loss of $148 million, translating to an EPS of ($2.12), was worse than the estimated ($2.27), indicating ongoing financial challenges. Additionally, complexities in the regulatory path and frequent manufacturing setbacks associated with its gene therapy products further heighten the uncertainty surrounding the company's financial outlook.

MGTX has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MeiraGTx Holdings plc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MeiraGTx Holdings plc (MGTX) Forecast

Analysts have given MGTX a Buy based on their latest research and market trends.

According to 6 analysts, MGTX has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MeiraGTx Holdings plc (MGTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.